KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases (2019 - 2025)

Esperion Therapeutics' Operating Leases history spans 7 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 48.13% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, down 48.13%, while the annual FY2025 figure was $2.8 million, 48.13% down from the prior year.
  • Operating Leases reached $2.8 million in Q4 2025 per ESPR's latest filing, up from $767000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.3 million in Q4 2024 to a low of $47000.0 in Q3 2022.
  • Average Operating Leases over 5 years is $1.9 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Operating Leases: tumbled 96.42% in 2022, then surged 4259.57% in 2023.
  • A 5-year view of Operating Leases shows it stood at $524000.0 in 2021, then increased by 26.91% to $665000.0 in 2022, then skyrocketed by 354.14% to $3.0 million in 2023, then soared by 75.86% to $5.3 million in 2024, then tumbled by 48.13% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Operating Leases are $2.8 million (Q4 2025), $767000.0 (Q3 2025), and $1.3 million (Q2 2025).